Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Deferred Taxes (2024 - 2025)

Indivior Pharmaceuticals has reported Deferred Taxes over the past 2 years, most recently at -$38.0 million for Q4 2025.

  • Quarterly results put Deferred Taxes at -$38.0 million for Q4 2025, down 202.7% from a year ago — trailing twelve months through Dec 2025 was -$46.0 million (down 757.14% YoY), and the annual figure for FY2025 was -$46.0 million, down 757.14%.
  • Deferred Taxes for Q4 2025 was -$38.0 million at Indivior Pharmaceuticals, down from -$15.0 million in the prior quarter.
  • Over the last five years, Deferred Taxes for INDV hit a ceiling of $37.0 million in Q4 2024 and a floor of -$38.0 million in Q4 2025.